How an Israeli biotech startup is plotting growth in Cambridge

Since its founding in Tel Aviv in 2017, neurodegenerative disease startup NeuroSense Therapeutics has been eyeing the U.S. market. Now, the company (Nasdaq: NRSN) is using its local headquarters in Cambridge to anchor its efforts to advance a drug that aims to treat amyotrophic lateral sclerosis (ALS).